<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783820</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_MMV390048_16_01</org_study_id>
    <nct_id>NCT02783820</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A</brief_title>
  <official_title>A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Network Services (CNS) Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q-Pharm Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>QIMR Berghofer Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study will evaluate the safety, tolerability and pharmacokinetic properties of&#xD;
      escalating single doses of reformulated MMV390048 when administered to healthy men and women&#xD;
      of non-childbearing potential (WNCBP) under fasted conditions (Part A).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I study will evaluate the safety, tolerability and pharmacokinetic properties of&#xD;
      escalating single doses of reformulated MMV390048 when administered to healthy men and women&#xD;
      of non-childbearing potential (WNCBP) under fasted conditions (Part A).&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      • To evaluate the safety and tolerability of single ascending doses of MMV390048 administered&#xD;
      orally to healthy subjects (men and WNCBP) under fasted conditions&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      • To describe the pharmacokinetics of MMV390048 in healthy subjects (men and WNCBP) after&#xD;
      single oral dose administration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MMV390048 - Number of Adverse Events</measure>
    <time_frame>28 days post administration of a single oral dose of MMV390048 to healthy volunteers</time_frame>
    <description>Number of observed and self-reported Adverse Events (AE) (unexpected toxicities, adverse events encountered during or after investigational drug administration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Cmax</measure>
    <time_frame>28 days</time_frame>
    <description>Estimation of the maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Tmax</measure>
    <time_frame>28 days</time_frame>
    <description>Estimation of the time to maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Total Exposure AUClast</measure>
    <time_frame>28 days</time_frame>
    <description>Estimation of the last quantifiable concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Total Exposure AUCinf</measure>
    <time_frame>28 days</time_frame>
    <description>Estimation of the area under the plasma concentration time curve over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Distribution and Clearance (CL/F)</measure>
    <time_frame>28 days</time_frame>
    <description>Apparent oral clearance (CL/F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Distribution and Clearance (Vz/F)</measure>
    <time_frame>28 days</time_frame>
    <description>Apparent volume of distribution (Vz/F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Distribution and Clearance (t½)</measure>
    <time_frame>28 days</time_frame>
    <description>Terminal half-life (t½) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>MMV390048 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MMV390048 40 mg, tablets, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match MMV390048 40 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match MMV390048 40 mg, tablets, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMV390048 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MMV390048 80 mg, tablets, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match MMV390048 80 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match MMV390048 80 mg, tablets, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMV390048 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MMV390048 120 mg, tablets, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match MMV390048 120 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match MMV390048 120 mg, tablets, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMV390048 40 mg</intervention_name>
    <arm_group_label>MMV390048 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match MMV390048 40 mg</intervention_name>
    <arm_group_label>Placebo to match MMV390048 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMV390048 80 mg</intervention_name>
    <arm_group_label>MMV390048 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match MMV390048 80 mg</intervention_name>
    <arm_group_label>Placebo to match MMV390048 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMV390048 120 mg</intervention_name>
    <arm_group_label>MMV390048 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match MMV390048 120 mg</intervention_name>
    <arm_group_label>Placebo to match MMV390048 120 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completion of the written informed consent process.&#xD;
&#xD;
          2. Men or WNCBP age 18 to 55 years, in good health as determined by past medical history,&#xD;
             physical examination, vital signs, electrocardiogram, and laboratory tests at&#xD;
             screening.&#xD;
&#xD;
          3. Male subjects agree to use acceptable methods of contraception if the male subject's&#xD;
             partner could become pregnant from the time of the first administration of study&#xD;
             medication until 130 (90+40) days following administration of the investigational&#xD;
             medicinal product. One of the following acceptable methods of contraception must be&#xD;
             utilized:&#xD;
&#xD;
               -  Condom and occlusive cap (diaphragm or cervical/vault caps)&#xD;
&#xD;
               -  Surgical sterilization (vasectomy with documentation of azoospermia) and a&#xD;
                  barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].&#xD;
&#xD;
               -  The subject's female partner uses oral contraceptives (combination&#xD;
                  estrogen/progesterone pills), injectable progesterone or subdermal implants and a&#xD;
                  barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].&#xD;
&#xD;
               -  The subject's female partner uses medically prescribed topically-applied&#xD;
                  transdermal contraceptive patch and a barrier method (condom or occlusive cap&#xD;
                  [diaphragm or cervical/vault caps].&#xD;
&#xD;
               -  The subject's female partner has undergone documented tubal ligation (female&#xD;
                  sterilization). In addition, a barrier method (condom or occlusive cap [diaphragm&#xD;
                  or cervical/vault caps].&#xD;
&#xD;
               -  The subject's female partner has undergone documented placement of an&#xD;
                  intrauterine device or intrauterine system. In addition, a barrier method (condom&#xD;
                  or occlusive cap [diaphragm or cervical/vault caps].&#xD;
&#xD;
               -  True abstinence: when this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception. Abstinent subjects have to agree to use 1 of the above-mentioned&#xD;
                  contraceptive methods, if they start sexual relationships during the study and&#xD;
                  for up to 100 days after the last dose of study drug.&#xD;
&#xD;
          4. Women subjects must be of non-childbearing potential (WNCBP) as per one of the&#xD;
             following definitions:&#xD;
&#xD;
               -  Natural (spontaneous) post-menopausal defined as being amenorrhoeic for at least&#xD;
                  12 months without an alternative medical cause with a screening follicle&#xD;
                  stimulating hormone level consistent with local laboratory levels for&#xD;
                  post-menopause.&#xD;
&#xD;
               -  Premenopausal with irreversible surgical sterilization by hysterectomy and/or&#xD;
                  bilateral oophorectomy or salpingectomy at least 6 months before screening (as&#xD;
                  determined by subject medical history).&#xD;
&#xD;
          5. Haematology, clinical chemistry and urinalysis results at screening that are within&#xD;
             the local laboratory reference range or, if outside the range, not clinically&#xD;
             significant as judged by the Investigator. More specifically, serum creatinine,&#xD;
             hepatic transaminase enzymes (AST ALT), and total bilirubin (unless the subject has&#xD;
             documented Gilbert syndrome) should not exceed the upper laboratory norm and&#xD;
             haemoglobin must be equal to or higher than the lower limit of the normal range.&#xD;
&#xD;
          6. Total body weight greater than 50 kg and a body mass index (BMI) within the range of&#xD;
             18 to 32 kg/m2 (inclusive).&#xD;
&#xD;
          7. Non-smoker or ex-smoker for more than 90 days prior to screening, or smoke no more&#xD;
             than 5 cigarettes per day as determined by history. Must be able to abstain from&#xD;
             smoking during the inpatient stay.&#xD;
&#xD;
          8. Willing and able to comply with all scheduled visits, treatment plan, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
          9. Agree to stay in contact with the study site for the duration of the study and up to 2&#xD;
             weeks following the end of study visit, provide updated contact information as&#xD;
             necessary, and have no current plans to move away from the study area for the duration&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male subjects with a female partner(s) who is (are) pregnant or lactating from the&#xD;
             time of the administration of study medication.&#xD;
&#xD;
          2. Women of childbearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, including women whose career, lifestyle, or sexual orientation&#xD;
             precludes intercourse with a male partner and women whose partners have been&#xD;
             sterilized by vasectomy or other means.&#xD;
&#xD;
          3. Evidence or history of clinically significant haematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal (including gallbladder), cardiovascular (including a&#xD;
             family history of long QT syndrome or sudden death), hepatic, psychiatric, neurologic,&#xD;
             or allergic disease (including drug or food allergies, anaphylaxis or other severe&#xD;
             allergic reactions but excluding untreated, asymptomatic, seasonal allergies at the&#xD;
             time of dosing).&#xD;
&#xD;
          4. History of malignancy of any organ system (other than localised basal cell carcinoma&#xD;
             of the skin), treated or untreated, within the past five years, regardless of whether&#xD;
             there is evidence of local recurrence or metastases.&#xD;
&#xD;
          5. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the Investigator, would make the subject&#xD;
             inappropriate for entry into this study.&#xD;
&#xD;
          6. Any surgical or medical condition possibly affecting drug absorption (e.g.&#xD;
             cholecystectomy, gastrectomy, bowel disease, etc.), distribution, metabolism or&#xD;
             excretion.&#xD;
&#xD;
          7. Previous splenectomy.&#xD;
&#xD;
          8. A history of photosensitivity.&#xD;
&#xD;
          9. Subject positive for any of the following&#xD;
&#xD;
               -  Anti-human immunodeficiency virus 1 or 2 antibodies (anti-HIV1 or anti-HIV2 Ab)&#xD;
                  (ELISA)&#xD;
&#xD;
               -  Hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
               -  Anti-hepatitis B core antibodies (anti-HBcAb)&#xD;
&#xD;
               -  Anti-hepatitis C antibodies (anti-HCV)&#xD;
&#xD;
         10. Resting vital signs (measured after 5 minutes in the supine position) at screening,&#xD;
             pre-dose (Part A) or pre-inoculation (Part B) outside of the following study-specific&#xD;
             normal ranges:&#xD;
&#xD;
               -  tympanic body temperature &lt; 38.0 °C&#xD;
&#xD;
               -  90 &lt; SBP &lt; 140 mmHg&#xD;
&#xD;
               -  50 &lt; DBP &lt; 90 mmHg&#xD;
&#xD;
               -  40 &lt; pulse rate &lt; 100 bpm&#xD;
&#xD;
         11. Symptomatic postural hypotension at screening, irrespective of the decrease in blood&#xD;
             pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood&#xD;
             pressure ≥20 mmHg 2 minutes after changing from a supine to standing position.&#xD;
&#xD;
         12. A history of clinically significant ECG abnormalities, or any of the following ECG&#xD;
             abnormalities at screening, pre-dose (Part A and B) or pre-inoculation (Part B):&#xD;
&#xD;
               -  PR &gt;210 ms&#xD;
&#xD;
               -  QRS complex &gt;120 ms&#xD;
&#xD;
               -  QTcF &gt;450 ms&#xD;
&#xD;
               -  Second or third degree atrioventricular block&#xD;
&#xD;
               -  Incomplete, complete or intermittent bundle branch block&#xD;
&#xD;
               -  Abnormal T wave morphology&#xD;
&#xD;
               -  Left ventricular hypertrophy with repolarisation abnormalities&#xD;
&#xD;
               -  Right ventricular hypertrophy.&#xD;
&#xD;
         13. Presence of acute infectious disease or fever (i.e. tympanic body temperature ≥38.5&#xD;
             ºC) within five days prior to the first dose of study medication (Part A) or the&#xD;
             inoculation administration (Part B).&#xD;
&#xD;
         14. Use of prescription or non-prescription drugs, herbal and dietary supplements within&#xD;
             14 days or 5 half-lives (whichever is the longer) prior to the first dose of study&#xD;
             medication (Part A) or the inoculation administration (Part B). [As an exception,&#xD;
             paracetamol may be used at doses of up to 1 g/day (Part A) or 2 g/day (Part B), or&#xD;
             ibuprofen up to 1.2 g/day (Part B). Limited use of other non-prescription medications&#xD;
             not believed to affect subject safety or the overall results of the study, may be&#xD;
             permitted on a case-by-case basis following approval by the sponsor.]&#xD;
&#xD;
         15. Recipient of any vaccination within 28 days prior to the first dose of study&#xD;
             medication (Part A) or the inoculation administration (Part B).&#xD;
&#xD;
         16. Urine drug screen at screening, pre-dose (Part A) or pre-inoculation (Part B) positive&#xD;
             for any drug as listed in Section 9.2.4 unless there is an explanation acceptable to&#xD;
             the medical Investigator (e.g. the subject has stated in advance that they consumed a&#xD;
             prescription or over the counter product which contained the detected drug) and/or the&#xD;
             subject has a negative urine drug screen on retest by the pathology laboratory.&#xD;
&#xD;
         17. Ingestion of any poppy seeds within the 24 hours prior to the screening blood test.&#xD;
&#xD;
         18. A positive alcohol breath test at screening, pre-dose (Part A) or pre-inoculation&#xD;
             (Part B).&#xD;
&#xD;
         19. History of regular alcohol consumption exceeding a weekly intake of more than 21 units&#xD;
             for males and more than 14 units for females (one unit is equivalent to 8-10 g of&#xD;
             ethanol, 285 ml of beer or lager, one glass [125 ml] of wine, or 25 ml of spirits)&#xD;
             within 6 months of screening.&#xD;
&#xD;
         20. History of drug habituation, or any prior intravenous usage of an illicit substance.&#xD;
&#xD;
         21. Participation in any investigational product study within 12 weeks or five half-lives&#xD;
             (whichever is longer) prior to the first dose of the study medication.&#xD;
&#xD;
         22. Intake of grapefruit, grapefruit juice or grapefruit-related citrus fruits (e.g.&#xD;
             Seville oranges, pomelos) within 28 days prior to the first dose of the study&#xD;
             medication.&#xD;
&#xD;
         23. Excessive consumption of beverages containing xanthine bases (e.g. more than 400 mg of&#xD;
             caffeine per day, equivalent to approximately 4 cups of coffee).&#xD;
&#xD;
         24. Pregnant or nursing (lactating) women.&#xD;
&#xD;
         25. Participation in any research study involving blood sampling (more than 450 ml/ unit&#xD;
             of blood), or blood donation to the Australian Red Cross Blood Service (ARCBS) or&#xD;
             other blood bank during the 8 weeks prior to IMP administration (Part A) or&#xD;
             inoculation (Part B).&#xD;
&#xD;
         26. Blood donation (excluding plasma donation) of any volume, within 1 month prior to&#xD;
             screening.&#xD;
&#xD;
         27. Medical requirement for intravenous immunoglobulin or blood transfusions.&#xD;
&#xD;
         28. Subject with poor peripheral venous access.&#xD;
&#xD;
         29. Subject unwilling or unable to comply with the restrictions described in this&#xD;
             protocol.&#xD;
&#xD;
         30. Any subject who, in the judgment of the Investigator, is likely to be noncompliant&#xD;
             during the study, or unable to cooperate because of a language problem or poor mental&#xD;
             development.&#xD;
&#xD;
         31. Any subject who is the Investigator or any sub-investigator, research assistant,&#xD;
             pharmacist, study coordinator, or other staff thereof, directly involved in conducting&#xD;
             the study.&#xD;
&#xD;
         32. Recent (within the last three years) and/or recurrent history of autonomic dysfunction&#xD;
             (e.g. recurrent episodes of fainting, palpitations, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarthy, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Q-Pharm Pty Ltd and QIMR Berghofer Medical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q Pharm Clinics</name>
      <address>
        <city>Herston</city>
        <zip>QLD 4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>May 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria, single ascending dose,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Clinical safety data (physical exam, ECG, vital signs, clinical score, AEs) lab safety data PK data PCR data Dosing completed, subject withdrawals,significant protocol deviations. Serious Adverse Event Reports</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pooled Placebo</title>
          <description>Pooled placebo from all cohorts (2 per cohort = 6)</description>
        </group>
        <group group_id="P2">
          <title>MMV390048 40 mg</title>
          <description>MMV390048 40 mg, tablets, single dose</description>
        </group>
        <group group_id="P3">
          <title>MMV390048 80 mg</title>
          <description>MMV390048 80 mg, tablets, single dose</description>
        </group>
        <group group_id="P4">
          <title>MMV390048 120 mg</title>
          <description>MMV390048 120 mg, tablets, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pooled Placebo</title>
          <description>Pooled placebo from all cohorts (2 per cohort = 6)</description>
        </group>
        <group group_id="B2">
          <title>MMV390048 40 mg</title>
          <description>MMV390048 40 mg, tablets, single dose</description>
        </group>
        <group group_id="B3">
          <title>MMV390048 80 mg</title>
          <description>MMV390048 80 mg, tablets, single dose</description>
        </group>
        <group group_id="B4">
          <title>MMV390048 120 mg</title>
          <description>MMV390048 120 mg, tablets, single dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="11.3"/>
                    <measurement group_id="B2" value="24.8" spread="2.5"/>
                    <measurement group_id="B3" value="23" spread="2.6"/>
                    <measurement group_id="B4" value="40.2" spread="13.9"/>
                    <measurement group_id="B5" value="30.3" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.1" spread="2.4"/>
                    <measurement group_id="B2" value="23.4" spread="1.9"/>
                    <measurement group_id="B3" value="24.3" spread="3.2"/>
                    <measurement group_id="B4" value="25.4" spread="3"/>
                    <measurement group_id="B5" value="24.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of MMV390048 - Number of Adverse Events</title>
        <description>Number of observed and self-reported Adverse Events (AE) (unexpected toxicities, adverse events encountered during or after investigational drug administration)</description>
        <time_frame>28 days post administration of a single oral dose of MMV390048 to healthy volunteers</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo from all cohorts (2 per cohort = 6)</description>
          </group>
          <group group_id="O2">
            <title>MMV390048 40 mg</title>
            <description>MMV390048 40 mg, tablets, single dose</description>
          </group>
          <group group_id="O3">
            <title>MMV390048 80 mg</title>
            <description>MMV390048 80 mg, tablets, single dose</description>
          </group>
          <group group_id="O4">
            <title>MMV390048 120 mg</title>
            <description>MMV390048 120 mg, tablets, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of MMV390048 - Number of Adverse Events</title>
          <description>Number of observed and self-reported Adverse Events (AE) (unexpected toxicities, adverse events encountered during or after investigational drug administration)</description>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Cmax</title>
        <description>Estimation of the maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Tmax</title>
        <description>Estimation of the time to maximum plasma concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Total Exposure AUClast</title>
        <description>Estimation of the last quantifiable concentration over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Total Exposure AUCinf</title>
        <description>Estimation of the area under the plasma concentration time curve over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Distribution and Clearance (CL/F)</title>
        <description>Apparent oral clearance (CL/F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Distribution and Clearance (Vz/F)</title>
        <description>Apparent volume of distribution (Vz/F) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Distribution and Clearance (t½)</title>
        <description>Terminal half-life (t½) over 28 days post administration of a single dose of MMV390048 using non-compartmental methods</description>
        <time_frame>28 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until Day 28</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pooled Placebo</title>
          <description>Pooled placebo from all cohorts (2 per cohort = 6)</description>
        </group>
        <group group_id="E2">
          <title>MMV390048 40 mg</title>
          <description>MMV390048 40 mg, tablets, single dose</description>
        </group>
        <group group_id="E3">
          <title>MMV390048 80 mg</title>
          <description>MMV390048 80 mg, tablets, single dose</description>
        </group>
        <group group_id="E4">
          <title>MMV390048 120 mg</title>
          <description>MMV390048 120 mg, tablets, single dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Medical device site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sterile pyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Suture insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Cristina Donini</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0312</phone>
      <email>doninic@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

